Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Tim H Brümmendorf, Patrick Ziegler, PhD, Jamil Akkad, MD, Ute Brassat, PhD, Lucia Vankann, Jens Panse, MD, Stefan Wilop, MD, Stefan Balabanov, MD, PhD, Klaus Schwarz, MD, Uwe M. Martens, MD, PhD, Hubert Schrezenmeier, MD

Blood (2011) 118 (21): 3427.

https://doi.org/10.1182/blood.V118.21.3427.3427

Published: 2011

Journal Articles

Functional p53 Is Required for Effective Telomerase Inhibition in BCRABL- Positive CML Cells in Vitro

Ute Brassat, Stefan Balabanov, Melanie Braig, Daniel Bali, Kerstin Borgmann, Tim H. Brummendorf

Blood (2008) 112 (11): 572.

https://doi.org/10.1182/blood.V112.11.572.572

Published: 2008

Journal Articles

Effective Telomerase Inhibition Via Expression of Dominant-Negative HTERT Leads to Altered Growth Kinetics, Elevated Apoptosis and Increased Radiosensitivity of Bcr-Abl-Positive K562 Cells In Vitro.

Ute Brassat, Stefan Balabanov, M.D., Ph.D., Henning Wege, M.D., Daniel Roessler, Kerstin Borgmann, M.D., Tim Brummendorf, MD

Blood (2007) 110 (11): 2935.

https://doi.org/10.1182/blood.V110.11.2935.2935

Published: 2007

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Ute Brassat, Stefan Balabanov, MD/PhD, Ulrike Hartmann, PhD, Daniel Rössler, Kerstin Borgmann, PhD, Judith Dierlamm, MD/PhD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 2185.

https://doi.org/10.1182/blood.V108.11.2185.2185

Published: 2006

Journal Articles

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler, Ulrike Hartmann, Winfried Kammer, Mhairi Copland, Ute Brassat, Martin Priemer, Ilona Hauber, Thomas Wilhelm, Gerold Schwarz, Lothar Kanz, Carsten Bokemeyer, Joachim Hauber, Tessa L. Holyoake, Alfred Nordheim, Tim H. Brümmendorf

Blood (2006) 109 (4): 1701–1711.

https://doi.org/10.1182/blood-2005-03-037648

Published: 2006

NARROW

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Functional p53 Is Required for Effective Telomerase Inhibition in BCRABL- Positive CML Cells in Vitro

Effective Telomerase Inhibition Via Expression of Dominant-Negative HTERT Leads to Altered Growth Kinetics, Elevated Apoptosis and Increased Radiosensitivity of Bcr-Abl-Positive K562 Cells In Vitro.

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Email alerts

ASH Publications

American Society of Hematology

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Functional p53 Is Required for Effective Telomerase Inhibition in BCRABL- Positive CML Cells in Vitro

Effective Telomerase Inhibition Via Expression of Dominant-Negative HTERT Leads to Altered Growth Kinetics, Elevated Apoptosis and Increased Radiosensitivity of Bcr-Abl-Positive K562 Cells In Vitro.

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only